US biotech Response Pharmaceuticals (Nasdaq: RSPN) has unveiled top-line Phase II results for its experimental obesity ...

China-based RemeGen has announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, ...

Danish CNS specialist Lundbeck has reported revenue grew 14% at constant exchange rates (CER), plus 14% DKK, to 12,258 ...

Clustered regularly interspaced short palindromic repeats (CRISPR)-based therapeutics are rapidly gaining traction for the ...

Sarepta Therapeutics, the US biotech, has sold around 9.3 million shares of Arrowhead Pharmaceuticals in a privately ...

US biotech Vedanta Biosciences has abandoned development of its ulcerative colitis candidate VE202 after the bacterial cocktail failed to outperform placebo in a mid-stage trial.

A voluntary rebate pilot for the 340B drug discount program is drawing attention as a potential way to address concerns over ...

Artificial intelligence is showing promise in improving the detection and management of idiopathic pulmonary fibrosis (IPF), ...

US pharma major AbbVie yesterday announced a $195 million investment in its North Chicago, Illinois manufacturing plant to ...

Texas, USA-based clinical-stage biotech Gameto, a clinical-stage biotechnology company developing stem cell-derived therapies ...

Sino-American biotech BeOne Medicines has announced financial results from the second quarter of 2025. Product revenue ...

UK-based contract research development and manufacturing organization (CRDMO) Arcinova, a subsidiary of Quotient Sciences, ...